Xcout IntelAscendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Subscribe to see Ascendis Pharma A/S’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ascendis Pharma A/S at a glance
Ascendis Pharma A/S is a biotech company headquartered in Hellerup, Denmark. It is publicly listed (ASND) with a market capitalisation of $14.7B. Xcout tracks 28 named people at Ascendis Pharma A/S, including Jan Moller Mikkelsen (President, Chief Executive Officer, Member of Executive Board & Executive Director).
Ascendis Pharma A/S leadership
- Jan Moller MikkelsenPresident, Chief Executive Officer, Member of Executive Board & Executive Director
- Scott T. SmithChief Financial Officer, Executive Vice President & Member of Executive Board
- Aimee D. ShuExecutive Vice President, Chief Medical Officer
- Jethro EkutaChief Regulatory & Safety Officer
- Lotte SønderbjergExecutive Vice President, Chief Administration Officer
- Michael Wolff JensenExecutive Vice President, Chief Legal Officer & Member of the Executive Board
22 more named people on record for Ascendis Pharma A/S, with roles, board committees and tenure — see the full roster →
Ascendis Pharma A/S competitors
A few of Ascendis Pharma A/S's closest competitors — see the full list of competitors and alternatives →
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue- and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently, VK2809 is undergoing Phase IIb clinical trials to address non-alcoholic steatohepatitis (NASH) confirmed by biopsy, as well as non-alcoholic fatty liver disease (NAFLD). The company's pipeline further features VK5211, an orally available non-steroidal selective androgen receptor modulator, which is in Phase II trials for patients convalescing from non-elective hip fracture surgery. Additionally, VK0612, an oral candidate poised for Phase IIb evaluation, targets type 2 diabetes. Lastly, VK0214, another orally administered TRß selective agonist, is being developed for X-linked adrenoleukodystrophy. Established in 2012, Viking Therapeutics maintains its corporate headquarters in San Diego, California.
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Forward Pharma A/S is a clinical-stage biotechnology company driven by research and discovery, with headquarters located in Denmark.
Amolyt Pharma is a biotechnology company focused on developing peptide therapeutics for rare endocrine and metabolic diseases. Its lead program, eneboparatide, is being developed for chronic hypoparathyroidism, serving patients with serious hormone-related disorders and the clinicians who treat them.
Acesis Holdings Corp. is a biomedical company that develops oral, non-steroid proprietary peptide drug candidates to treat metabolic and endocrine disorders, with an initial focus on male hypogonadism and related co-morbidities. The company serves patients experiencing declining testosterone levels by providing alternatives designed to stimulate natural testosterone production.
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
Get Ascendis Pharma A/S's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ascendis Pharma A/S in Xcout Intel
- 28 named people with titles, LinkedIn and board committees
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access